Evidence map›Paper›PMID 38835971›Full record

ArticleMedizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V2024

Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms - a practical guide to WHO-HAEM5.

Constanze Kühn, Katharina Hörst, Hans M Kvasnicka, Andreas Hochhaus, Andreas Reiter

Abstract read
In one paragraph

Article in Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Constanze KühnMLL - Munich Leukemia Laboratory Munich Germany.ORCID https://orcid.org/0009-0007-7630-8545
Katharina HörstMLL - Munich Leukemia Laboratory Munich Germany.ORCID https://orcid.org/0009-0007-6276-614X
Hans M KvasnickaUniversity Hospital Institute for Pathology and Molecular Pathology Wuppertal Germany.ORCID https://orcid.org/0000-0002-3081-1395
Andreas HochhausUniversitätsklinikum Jena Abteilung Hämatologie und Internistische Onkologie, Klinik für Innere Medizin II Jena Germany.ORCID https://orcid.org/0000-0003-0626-0834
Andreas ReiterIII. Medizinische Klinik Medical Clinic for Haematology and Oncology, University Medical Centre Mannheim Mannheim Germany.ORCID https://orcid.org/0000-0002-7718-6507

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Within the World Health Organization (WHO) classification of haematopoietic neoplasms, particularly its fifth version from 2022 (WHO-HAEM5), myeloid neoplasms are not only grouped into myeloproliferative (MPN) and myelodysplastic neoplasms (MDS). There is also a group of haematological disorders that share features of both categories termed myelodysplastic /myeloproliferative neoplasms (MDS/MPN). In this article, we aim to provide a comprehensive and practical guide to WHO-HAEM5 highlighting the genetic alterations that underlie MPN and MDS/MPN. This guide provides an overview of the overlapping commonalities among these entities, as well as their unique characteristics.

Indexed as

classificationHAEM5myelodysplastic /myeloproliferative neoplasmsmyeloproliferative neoplasmsoverlapWHO

Identifiers

PMID38835971
PMCPMC11006376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.